Pharmafile Logo
Pharmafocus logo
Advanced Search

acute coronary syndrome

Showing 4 posts of 4 posts found.

shutterstock_76507048

Acute coronary syndrome market to grow to over $12 billion by 2022

August 15, 2016
Research and Development, Sales and Marketing GlobalData, acute coronary syndrome

The acute coronary syndrome (ACS) market is forecast to rise from $7.8 billion in 2015 to $12.1 billion by 2022 …

News
Brilinta image

AstraZeneca’s troubled Brilinta gets welcome lift

January 14, 2015
Sales and Marketing AstraZeneca, Brilinta, FDA, US Department of Justice, acute coronary syndrome, ticagrelor

AstraZeneca has reported positive primary endpoint results for its anti-clogging drug Brilinta to treat patients who have had a heart …

News

Merck suffers late-stage blow to vorapaxar

January 18, 2011
Research and Development ACS, Merck & Co, acute coronary syndrome, anticoagulant, heart attack, peripheral arterial disease, stroke, vorapaxar

An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.The Data and Safety Monitoring …

News
AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor)

FDA delays approval of AstraZeneca’s Brilinta

December 20, 2010
Research and Development, Sales and Marketing AZ, AstraZeneca, Brilinta, Brilique, acute coronary syndrome

US regulators have delayed approving AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor) because their want more information about a crucial clinical trial. …

News
The Gateway to Local Adoption Series

Latest content

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026